Henry Schein\u2019s powerful nationwide distribution network, comprised of more than 400 medical field sales and telesales representatives, will provide marketing support for the inFoods\u00ae IBS test to primary care and gastroenterology specialty practices. With more than 93 years in health care innovation and over $12 billion in annual sales in 2024, Henry Schein is well-positioned to accelerate adoption of this new, non-pharmaceutical precision-based diagnostic therapy for patients suffering from IBS.<\/p>\n
\u201cWe are thrilled to partner with Henry Schein to bring inFoods\u00ae IBS test to more patients and providers across the country,\u201d said Zack Irani, CEO of Biomerica. \u201cTheir national reach and proven track record in delivering innovative medical products will help accelerate adoption of our non-drug, personalized solution for IBS management.\u201d<\/p>\n
\u201cOur team is dedicated to offering health care professionals the latest innovative solutions that ultimately enhance patient care, and we are pleased to collaborate with Biomerica to showcase the inFoods\u00ae IBS test in the United States,\u201d said Ty Ford, Vice President and General Manager of Sales for Henry Schein Medical. \u201cThe inFoods\u00ae IBS test offers a science-based therapy that helps to address one of the most common GI disorders, providing support for individuals experiencing IBS symptoms.\u201d<\/p>\n
Recently Published Clinical Study in Leading Journal – Gastroenterology<\/p>\n
A multicenter, double-blinded clinical study on the inFoods\u00ae IBS test was published in the June issue of Gastroenterology, the top peer-reviewed GI journal. As the largest study of its kind, it demonstrated statistically significant outcomes:<\/p>\n
59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA\u2019s endpoint for abdominal pain reduction, compared to 42.2% in the control group.Among IBS-C patients, 67.1% of patients in the treatment group vs. 35.8% in the control group.Among IBS-M patients, 66% of patients in the treatment group vs. 29.5% in the control group. <\/p>\n
These results highlight inFoods\u00ae IBS test as the only targeted therapy to demonstrate efficacy specifically in IBS-M patients, a subgroup historically underserved by existing treatments. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center.\u00a0\u00a0\u00a0<\/p>\n
A Widespread Condition with Significant Unmet Need
Irritable bowel syndrome (IBS) affects about 10% to 15% of adults in the United States. Studies have shown that individuals who have IBS report a lower health-related quality of life and decreased work productivity. Individuals with IBS experience various symptoms, including abdominal pain and cramps. Some factors, such as certain foods, can worsen symptoms and cause flare-ups.<\/p>\n
About inFoods\u00ae IBS<\/p>\n
inFoods\u00ae IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient\u2019s immune response\u2014offering a non-pharmaceutical, precision-based approach to symptom relief.<\/p>\n
For more information about inFoods\u00ae IBS, visit www.inFoodsibs.com<\/a>.<\/p>\n InFoods IBS is Laboratory Developed Test (LDT) used within a single laboratory that is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.<\/p>\n About Henry Schein, Inc. (Nasdaq: HSIC)<\/p>\n Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members<\/a> worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental<\/a> and medical<\/a> practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories<\/a>, government and institutional health care clinics<\/a>, as well as other alternate care sites.\u00a0\u00a0\u00a0\u00a0<\/p>\n Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.\u00a0\u00a0<\/p>\n A FORTUNE 500 Company and a member of the S&P 500\u00ae index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company’s sales reached $12.7 billion in 2024 and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.\u00a0\u00a0<\/p>\n For more information, visit Henry Schein at\u00a0
www.henryschein.com<\/a>, Facebook.com\/HenrySchein<\/a>, Instagram.com\/HenrySchein<\/a>, LinkedIn.com\/Company\/HenrySchein,<\/a> and @HenrySchein on X<\/a>.\u00a0\u00a0\u00a0\u00a0<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/Biomerica-Inc-.png\")